Le Lézard
Classified in: Health
Subjects: SVY, MRR

Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), and End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The comprehensive market study indicates a compounded annual growth rate of 5.6% leading up to 2031, highlighting the escalating urgency to tackle the diverse types of cancer more effectively. A surge in cancer research funding, combined with a solid backing of initiatives aimed at promoting early detection, are key factors enhancing the market's potential. Specialists are particularly bullish about the strides in precision diagnostics, presenting ground-breaking opportunities within the sector.

The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent. Detailed analysis points to significant market expansion, driven by the increasing incidence of cancer and a potent rise in the region's readiness to adopt cutting-edge diagnostic technologies.

Key Market Dynamics Shaping Europe's Cancer Diagnostics

Despite the optimism, the market faces challenges such as the high costs associated with imaging systems and a pronounced skills gap that hinders optimum implementation of comprehensive screening programs.

Products and Innovations: Spotlight on the IVD Segment

The predictive analytics within the report signposts the In Vitro Diagnostics (IVD) as the dominant sector. Its substantial market share is directly linked to technological advancements and the broad spectrum of reagents and consumables enabling clinicians to navigate cancer diagnosis with enhanced accuracy and efficiency.

Breast Cancer Diagnosis Leads the Cancer Type Segments

Breast cancer diagnostics stands as a notable segment bolstered by growing healthcare investment and reimbursement adjustments for cutting-edge technologies like Next-Generation Sequencing (NGS). Notably, an increase in awareness programs led by renowned medical establishments is significantly influencing the diagnostics landscape.

End Users: Hospitals & Diagnostic Laboratories at the Forefront

Hospitals and diagnostic laboratories are envisaged to maintain a stronghold in the end-user segment. Their significant market share is a testament to their pivotal role in harnessing advanced diagnostics, scaling up cancer care protocols, and the extension of their state-of-the-art infrastructural facilities.

Regional Insights: Germany Leads Amidst High Growth in European Countries

Among the EU nations, Germany is anticipated to command the lion's share of the market. Factors such as the country's proactive approach to cancer awareness, widespread acceptance of advanced diagnostic solutions, and robust healthcare expenditure contribute to this leadership stance.

Forecasts Through 2031:

The market size, segment analysis, and country-wise breakdowns encapsulated in the report provide investors, healthcare providers, and policymakers with a comprehensive understanding of the current trends and future projections in cancer diagnostics. The document acts as a crucial guide in strategic planning and resource allocation across Germany, France, the UK, Italy, Spain, Switzerland, the Netherlands, and the rest of the European region.

Notable stakeholders in the market, such as industry-leading healthcare companies and tech innovators, continue to push the envelope in diagnostic precision, striving to make early and accurate cancer detection more accessible to patients across Europe.

The insights gained through this report empower stakeholders to navigate the market with greater clarity, optimize their operational models, and ultimately, contribute to the betterment of cancer diagnostics outcomes for patients throughout Europe.

Key questions answered in the report:

Market Insights

Factors Affecting Market Growth


Regulatory Analysis

Porter's Five Forces Analysis: Diagnostic Imaging Technologies for Cancer Screening

Porter's Five Forces Analysis: IVD Technologies for Cancer Screening

Pricing Analysis

Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)

Competition Analysis

Scope of the Report:

In Vitro Diagnostics
(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)

Diagnostic Imaging
(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)

(Other imaging consumables include films, gels, transducers, and probes, among others)

Europe Cancer Diagnostics Market Size & Trend Analysis - by Cancer Type

Note: Other cancer types include leukemia, lymphoma, stomach, ovarian, melanoma, kidney, and cervical cancers.

Europe Cancer Diagnostics Market Size & Trend Analysis - by End User

Europe Cancer Diagnostics Market Size & Trend Analysis - by Country

For more information about this report visit https://www.researchandmarkets.com/r/9uj181

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

These press releases may also interest you

at 13:00
Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of...

13 avr 2024
Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver....

13 avr 2024
MyAdvisor, a holistic wellness technology company, has been awarded the 2023-2024 Platinum Level Bell Seal...

13 avr 2024
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDEtm) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data...

13 avr 2024
On Apr. 11, 2024, VITAL HealthCare, one of the 5 core business divisions of the VITAL Group, marked a stunning debut at the 89th China International Medical Equipment Fair (CMEF) in Shanghai. Drawing on the Group's core competence in R&D and its...

12 avr 2024
The report titled "STD Testing Market by Type (Blood Tests, Lumbar Puncture, Swab Tests), Product Type (Instruments, Reagents & Kits), Test Settings, Indication, End-user - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

News published on and distributed by: